Skip to content
2000
Volume 21, Issue 4
  • ISSN: 2666-0822
  • E-ISSN: 2666-0830

Abstract

Background

This study aimed to compare the efficacy and tolerability of mirtazapine and sertraline in moderately depressed patients undergoing chronic hemodialysis therapy.

Methods

In this double-blind clinical study, 54 hemodialysis patients diagnosed with moderate to severe depression, scoring greater than 18 on the Beck Depression Inventory, version II (BDI-II), were randomly assigned to receive 12 weeks of treatment with either mirtazapine (15mg/day) plus placebo or sertraline (50 mg/day) plus placebo. Efficacy outcomes were assessed by evaluating changes in baseline BDI-II scores, as well as rates of response and remission at weeks 2, 4, 8, and 12 of treatment. The impact of the antidepressant treatment on the patient’s health-related quality of life was also assessed at the end of the treatment phase, with ratings ranging from 0 (the worst impact) to 10 (the best impact). Safety and tolerability of the study medications were monitored using an antidepressant side effect checklist and through spontaneous participant reports. Both efficacy and tolerability analyses were conducted on the intent-to-treat sample. The -values less than 0.01 based on Bonferroni's multiple-testing correction method were considered statistically significant.

Results

The mixed models for repeated measures analysis revealed a significant time effect on depression symptoms ( < 0.001), indicating improvement in both treatment groups over the study period. However, the treatment effect was not significant ( = 0.160), suggesting no overall difference in depressive symptoms between groups. The interaction between time and treatment was significant ( = 0.020), indicating varying changes in depressive symptoms over time between treatment groups. At week two, patients receiving mirtazapine had a lower mean BDI-II score than those receiving sertraline (15.62±5.24 18.92±5.03), but the difference between the groups was not statistically significant (-value = 0.022). Subsequent assessments at weeks 4, 8, and 12 showed comparable mean BDI-II scores between both treatment groups. Furthermore, at all assessment points, the rate of responders (≥50% reduction in BDI-II total score from baseline) and the rate of remitters (BDI-II total score of <10) were similar between the treatment groups. However, mirtazapine-treated patients scored higher in assessing the overall impact of the treatment on their quality of life compared to the sertraline-treated group (7.40±1.18 6.51±1.15 -value = 0.007). Regarding safety and tolerability, although there were differences in the pattern of adverse effects between the treatment groups, the proportion of patients experiencing at least one adverse effect and the rate of dropouts were similar between the two groups, indicating comparable tolerability for both medications.

Conclusion

Our results suggest that the efficacy and tolerability of mirtazapine are equivalent to those of sertraline in treating moderate depression in hemodialysis patients. However, mirtazapine appears to have a more favorable effect on patients' health-related quality of life compared to sertraline.

Trial Registration

The trial was registered at the Iranian Registry of Clinical Trials (https://www.irct.ir/trial/66756, identifier code: IRCT20120215009014N445). Registration date: 2022-11-09.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cprr/10.2174/0126660822312474240827051942
2024-09-09
2025-11-14

  • From This Site

    /content/journals/cprr/10.2174/0126660822312474240827051942
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. PalmerS. VecchioM. CraigJ.C. Prevalence of depression in chronic kidney disease: Systematic review and meta-analysis of observational studies.Kidney Int.201384117919110.1038/ki.2013.7723486521
     [Google Scholar]
  2. BautovichA. KatzI. SmithM. LooC.K. HarveyS.B. Depression and chronic kidney disease: A review for clinicians.Aust. N. Z. J. Psychiatry201448653054110.1177/000486741452858924658294
     [Google Scholar]
  3. ShirazianS. GrantC.D. AinaO. MattanaJ. KhorassaniF. RicardoA.C. Depression in chronic kidney disease and end-stage renal disease: Similarities and differences in diagnosis, epidemiology, and management.Kidney Int. Rep.2017219410710.1016/j.ekir.2016.09.00529318209
     [Google Scholar]
  4. MartinC.R. ThompsonD.R. Prediction of quality of life in patients with end‐stage renal disease.Br. J. Health Psychol.200051415510.1348/135910700168757
     [Google Scholar]
  5. HedayatiS.S. FinkelsteinF.O. Epidemiology, diagnosis, and management of depression in patients with CKD.Am. J. Kidney Dis.200954474175210.1053/j.ajkd.2009.05.00319592143
     [Google Scholar]
  6. WatnickS. KirwinP. MahnensmithR. ConcatoJ. The prevalence and treatment of depression among patients starting dialysis.Am. J. Kidney Dis.200341110511010.1053/ajkd.2003.5002912500227
     [Google Scholar]
  7. WhittyP. GilbodyS. NICE, but will they help people with depression? The new National Institute for Clinical Excellence depression guidelines.Br. J. Psychiatry2005186317717810.1192/bjp.186.3.17715738494
     [Google Scholar]
  8. PalmerS.C. NataleP. RuospoM. Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis.Cochrane Database Syst. Rev.201620165CD00454110.1002/14651858.CD004541.pub3
     [Google Scholar]
  9. KubanekA. PaulP. PrzybylakM. Use of sertraline in hemodialysis patients.Medicina (Kaunas)202157994910.3390/medicina5709094934577872
     [Google Scholar]
  10. YalcinA.U. SahinG. ErolM. BalC. Sertraline hydrochloride treatment for patients with hemodialysis hypotension.Blood Purif.200220215015310.1159/00004700111818677
     [Google Scholar]
  11. RazeghiE. Dashti-KhavidakiS. NassiriS. A randomized crossover clinical trial of sertraline for intradialytic hypotension.Iran. J. Kidney Dis.20159432333026174461
     [Google Scholar]
  12. ShakibaM. SanadgolH. AzmoudeH.R. MashhadiM.A. SharifiH. Effect of sertraline on uremic pruritus improvement in ESRD patients.Int. J. Nephrol.2012202136390110.1155/2012/363901
     [Google Scholar]
  13. ChanK.Y. LiC.W. WongH. Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients.J. Palliat. Med.201316896697010.1089/jpm.2012.050423777329
     [Google Scholar]
  14. AnttilaS.A.K. LeinonenE.V.J. A review of the pharmacological and clinical profile of mirtazapine.CNS Drug Rev.20017324926410.1111/j.1527‑3458.2001.tb00198.x11607047
     [Google Scholar]
  15. NuttD.J. Tolerability and safety aspects of mirtazapine.Hum. Psychopharmacol.200217S1Suppl. 1S37S4110.1002/hup.38812404669
     [Google Scholar]
  16. ThompsonC. Mirtazapine versus selective serotonin reuptake inhibitors.J. Clin. Psychiatry199960Suppl. 17182210446737
     [Google Scholar]
  17. ThaseM.E. NierenbergA.A. VrijlandP. van OersH.J.J. SchutteA.J. SimmonsJ.H. Remission with mirtazapine and selective serotonin reuptake inhibitors: A meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.Int. Clin. Psychopharmacol.201025418919810.1097/YIC.0b013e328330adb220531012
     [Google Scholar]
  18. ShibataK. ShinzatoT. SattaH. SP704 The effect of mirtazapine in dialysis patient with appetite loss.Nephrol. Dial. Transplant.201530Suppl. 3iii611-110.1093/ndt/gfv200.23
     [Google Scholar]
  19. GholyafM. SheikhV. YasrebifarF. MohammadiY. MirjaliliM. MehrpooyaM. Effect of mirtazapine on pruritus in patients on hemodialysis: A cross-over pilot study.Int. Urol. Nephrol.20205261155116510.1007/s11255‑020‑02473‑332383050
     [Google Scholar]
  20. MehrpooyaM. GholyafM. YasrebifarF. MohammadiY. SheikhV. Evaluation of efficacy of mirtazapine on pruritus and serum histamine and serotonin levels in patients undergoing hemodialysis: A before–after pilot clinical trial.Int. J. Nephrol. Renovasc. Dis.20201312913810.2147/IJNRD.S24639332547158
     [Google Scholar]
  21. APADiagnostic and statistical manual of mental disorders.Washington, D.C.The American Psychiatric Association2013
     [Google Scholar]
  22. BeckA.T. SteerR.A. BrownG. Beck depression inventory–II.1996Available from: [https://psycnet.apa.org/doiLanding?doi=10.1037%2Ft00742-000]
    [Google Scholar]
  23. SheehanD.V. LecrubierY. SheehanK.H. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.J. Clin. Psychiatry19985920Suppl. 2022339881538
     [Google Scholar]
  24. NejatisafaA.A. SharafiE. MotamedM. Persian translation and cultural adaptation of mini international neuropsychiatric interview and its psychometric properties.Arch. Iran Med.202225529429910.34172/aim.2022.4835943004
     [Google Scholar]
  25. NaglerE.V. WebsterA.C. VanholderR. ZoccaliC. Antidepressants for depression in stage 3–5 chronic kidney disease: A systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP).Nephrol. Dial. Transplant.201227103736374510.1093/ndt/gfs29522859791
     [Google Scholar]
  26. HedayatiS.S. BosworthH.B. KuchibhatlaM. KimmelP.L. SzczechL.A. The predictive value of self-report scales compared with physician diagnosis of depression in hemodialysis patients.Kidney Int.20066991662166810.1038/sj.ki.500030816598203
     [Google Scholar]
  27. HamidiR. FekrizadehZ. AzadbakhtM. Validity and reliability Beck Depression Inventory-II among the Iranian elderly population.J Sabzevar Univ Med Sci2015221189198
     [Google Scholar]
  28. YohannesA.M. DoddM. MorrisJ. WebbK. Reliability and validity of a single item measure of quality of life scale for adult patients with cystic fibrosis.Health Qual. Life Outcomes20119110510.1186/1477‑7525‑9‑10522117573
     [Google Scholar]
  29. WatanabeN. OmoriI.M. NakagawaA. Mirtazapine versus other antidepressive agents for depression.Cochrane Database Syst. Rev.2011712CD00652810.1002/14651858.CD006528.pub2
     [Google Scholar]
  30. NaranjoC.A. BustoU. SellersE.M. A method for estimating the probability of adverse drug reactions.Clin. Pharmacol. Ther.198130223924510.1038/clpt.1981.1547249508
     [Google Scholar]
  31. TarazM. KhatamiM.R. Dashti-KhavidakiS. Sertraline decreases serum level of interleukin-6 (IL-6) in hemodialysis patients with depression: Results of a randomized double-blind, placebo-controlled clinical trial.Int. Immunopharmacol.201317391792310.1016/j.intimp.2013.09.02024121064
     [Google Scholar]
  32. WatanabeN. OmoriI.M. NakagawaA. Mirtazapine versus other antidepressants in the acute-phase treatment of adults with major depression: Systematic review and meta-analysis.J. Clin. Psychiatry20086991404141510.4088/JCP.v69n090819193341
     [Google Scholar]
  33. CiprianiA. FurukawaT.A. SalantiG. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis.Lancet2009373966574675810.1016/S0140‑6736(09)60046‑519185342
     [Google Scholar]
  34. VersianiM. MorenoR. Ramakers-van MoorselC.J.A. SchutteA.J. Antidepressants Study Grp CE. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients.CNS Drugs200519213714610.2165/00023210‑200519020‑0000415697327
     [Google Scholar]
  35. BenkertO. SzegediA. KohnenR. Mirtazapine compared with paroxetine in major depression.J. Clin. Psychiatry200061965666310.4088/JCP.v61n091111030486
     [Google Scholar]
  36. FavaM. DunnerD.L. GreistJ.H. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: An open-label trial.J. Clin. Psychiatry200162641342010.4088/JCP.v62n060311465517
     [Google Scholar]
  37. KellerM.B. PinderR.M. The role of mirtazapine in the pharmacotherapy of depression.J. Clin. Psychiatry200061860961610.4088/JCP.v61n081210982209
     [Google Scholar]
  38. ChristodoulouC. DouzenisA. MoussasG. LykourasL. Effectiveness of mirtazapine in the treatment of postherpetic neuralgia.J. Pain Symptom Manage.2010394e3e610.1016/j.jpainsymman.2009.11.31120413051
     [Google Scholar]
  39. WernerF.M. CoveñasR. Classical neurotransmitters and neuropeptides involved in major depression: A review.Int. J. Neurosci.2010120745547010.3109/00207454.2010.48365120583898
     [Google Scholar]
  40. BlierP. Neurotransmitter targeting in the treatment of depression.J. Clin. Psychiatry201374Suppl. 2192410.4088/JCP.12084su1c.0424191974
     [Google Scholar]
  41. JainR. Single-action versus dual-action antidepressants.Prim. Care Companion J. Clin. Psychiatry20046Suppl. 171116001091
     [Google Scholar]
  42. KasperS. Clinical efficacy of mirtazapine: A review of meta-analyses of pooled data.Int. Clin. Psychopharmacol.199510Suppl. 4253510.1097/00004850‑199512004‑000058930007
     [Google Scholar]
  43. QuitkinF.M. TaylorB.P. KremerC. Does mirtazapine have a more rapid onset than SSRIs?J. Clin. Psychiatry200162535836110.4088/JCP.v62n050911411818
     [Google Scholar]
  44. NuttD. WilsonS. PatersonL. Sleep disorders as core symptoms of depression.Dialogues Clin. Neurosci.200810332933610.31887/DCNS.2008.10.3/dnutt18979946
     [Google Scholar]
  45. TillerJ.W.G. Depression and anxiety.Med. J. Aust.2013199S6S28S3110.5694/mja12.1062825370281
     [Google Scholar]
  46. LeinonenE. SkarsteinJ. BehnkeK. ÅgrenH. HelsdingenJ.T. GroupN.A.S. Efficacy and tolerability of mirtazapine versus citalopram: A double-blind, randomized study in patients with major depressive disorder.Int. Clin. Psychopharmacol.199914632933710.1097/00004850‑199911000‑0000210565799
     [Google Scholar]
  47. HashimotoT. ShiinaA. HasegawaT. Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: A pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial.Ann. Gen. Psychiatry20161512710.1186/s12991‑016‑0115‑127777607
     [Google Scholar]
  48. FergusonJ.M. SSRI antidepressant medications: Adverse effects and tolerability.Prim. Care Companion J. Clin. Psychiatry200131222715014625
     [Google Scholar]
  49. Machado-VieiraR. SalvadoreG. LuckenbaughD.A. ManjiH.K. ZarateC.A.Jr Rapid onset of antidepressant action: A new paradigm in the research and treatment of major depressive disorder.J. Clin. Psychiatry200869694695810.4088/JCP.v69n061018435563
     [Google Scholar]
  50. AlmutaryH. BonnerA. DouglasC. Symptom burden in chronic kidney disease: A review of recent literature.J. Ren. Care201339314015010.1111/j.1755‑6686.2013.12022.x23826803
     [Google Scholar]
  51. KinomuraM. IiharaH. FujiiH. Effect of mirtazapine for the prevention of nausea and vomiting in patients with thoracic cancer receiving platinum-based chemotherapy.Anticancer Res.20234331301130710.21873/anticanres.1627736854494
     [Google Scholar]
  52. FreynhagenR. Muth-SelbachU. LipfertP. The effect of mirtazapine in patients with chronic pain and concomitant depression.Curr. Med. Res. Opin.200622225726410.1185/030079906X8048616466597
     [Google Scholar]
  53. SchreiberS. RigaiT. KatzY. PickC.G. The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms.Brain Res. Bull.200258660160510.1016/S0361‑9230(02)00825‑012372565
     [Google Scholar]
  54. GökçeŞ.F. ÇiğdemB. Efficacy of mirtazapine in neuropathic pain model.Anadolu Psikiyatri Derg.2020215461467
     [Google Scholar]
  55. ZhuJ. WeiX. FengX. SongJ. HuY. XuJ. Repeated administration of mirtazapine inhibits development of hyperalgesia/allodynia and activation of NF-κB in a rat model of neuropathic pain.Neurosci. Lett.20084331333710.1016/j.neulet.2007.12.03718248895
     [Google Scholar]
  56. TheobaldD.E. KirshK.L. HoltsclawE. DonaghyK. PassikS.D. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.J. Pain Symptom Manage.200223544244710.1016/S0885‑3924(02)00381‑012007762
     [Google Scholar]
  57. KamphuisJ. TaxisK. Schuiling-VeningaC.C.M. BruggemanR. LancelM. Off-label prescriptions of low-dose quetiapine and mirtazapine for insomnia in the Netherlands.J. Clin. Psychopharmacol.201535446847010.1097/JCP.000000000000033826035053
     [Google Scholar]
  58. SanL. ArranzB. Mirtazapine: Only for depression?Acta Neuropsychiatr.2006183-413014310.1111/j.1601‑5215.2006.00143.x26989965
     [Google Scholar]
  59. QuimbyJ.M. LunnK.F. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: A masked placebo-controlled crossover clinical trial.Vet. J.2013197365165510.1016/j.tvjl.2013.05.04823838205
     [Google Scholar]
  60. QuimbyJ.M. BensonK.K. SummersS.C. Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease.J. Feline Med. Surg.202022437638310.1177/1098612X1985130331161850
     [Google Scholar]
  61. KhannaR. BoozalisE. BelzbergM. ZampellaJ.G. KwatraS.G. Mirtazapine for the treatment of chronic pruritus.Medicines (Basel)2019637310.3390/medicines603007331284577
     [Google Scholar]
  62. GelenbergA.J. LaukesC. McGahueyC. Mirtazapine substitution in SSRI-induced sexual dysfunction.J. Clin. Psychiatry200061535636010.4088/JCP.v61n050610847310
     [Google Scholar]
  63. KoutouvidisN. PratikakisM. FotiadouA. The use of mirtazapine in a group of 11 patients following poor compliance to selective serotonin reuptake inhibitor treatment due to sexual dysfunction.Int. Clin. Psychopharmacol.199914425325510.1097/00004850‑199907000‑0000810468319
     [Google Scholar]
  64. ChaeJ-H. LeeK-U. ShinY-K. Comparison of side effect profiles between mirtazapine and selective serotonin reuptake inhibitors; a naturalistic setting.Clin. Psychopharmacol. Neurosci.2004213135
     [Google Scholar]
  65. CankurtaranE.S. OzalpE. SoygurH. AkbiyikD.I. TurhanL. AlkisN. Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: Superiority over imipramine.Support. Care Cancer200816111291129810.1007/s00520‑008‑0425‑118299900
     [Google Scholar]
  66. KhalilianA. AhmadimoghaddamD. SakiS. MohammadiY. MehrpooyaM. A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome.Biopsychosoc. Med.2021151310.1186/s13030‑021‑00205‑233536043
     [Google Scholar]
/content/journals/cprr/10.2174/0126660822312474240827051942
Loading
Safety and Efficacy of Mirtazapine Compared to Sertraline in Hemodialysis Patients with Major Depressive Disorder: A Randomized Controlled Clinical Trial
Curr Psyc Res Rev 21, 590 (2025); https://doi.org/10.2174/0126660822312474240827051942
/content/journals/cprr/10.2174/0126660822312474240827051942
/content/journals/cprr/10.2174/0126660822312474240827051942
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): antidepressants; Depression; ESRD; hemodialysis; mirtazapine; sertraline

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test